Disclosure: We may have a financial affiliation with some entities featured on this page. Rankings are editorial; see our methodology.
Educational content — not medical advice. Menopause Brief is an independent educational publisher, not a clinic, pharmacy, or telehealth provider. We do not diagnose, prescribe, or book consults.
Why the #1–#3 order landed here
Midlife readers comparing menopause telehealth face a crowded field: specialty clinics, FDA-approved hormone pathways, compounded models, marketplaces, and programs combining hormone and metabolic care. Our Wave 1 ranking heavily weights Trustpilot and Google reviews, then layers scope fit, care-model clarity, pricing/eligibility transparency, and reputation context.
This brief explains the September 23, 2026 evidence pass without inventing scores or using endorsement seals. Trustpilot figures were verified live on 2026-09-23 (ET). Google Business Profile aggregates remain TBD where a stable primary profile was not confirmed.
What “heavily weighted reviews” means
| Signal | What we use | What we do not claim |
|---|---|---|
| Trustpilot | TrustScore, volume, access date, and sample depth | That high stars equal clinical efficacy |
| Primary Maps rating and volume when verifiable | Invented or unconfirmed scores |
#1 — Ivim Health
Trustpilot (verified live 2026-09-23 ET): 4.9 / 5 across 39,575 reviews. Google: TBD — verify before publish.
Why #1: Ivim’s very large, high Trustpilot signal is the strongest in this set. Public materials describe women’s hormone pathways alongside GLP-1 and metabolic programs, matching the midlife weight + hormone scope. This is a methodology outcome, not a clinical efficacy score.
#2 — Winona
Trustpilot (verified live 2026-09-23 ET): 4.6 / 5 across 8,474 reviews. Google: TBD — verify before publish.
Winona’s Trustpilot score × volume is the strongest menopause-forward signal after Ivim. Its cash-pay menopause hormone model fits the specialty audience, but its public positioning is less centered on one coordinated weight + hormone ecosystem. Compounded products, when prescribed, are not FDA-approved; state lists and care details change.
#3 — Alloy
Trustpilot (verified live 2026-09-23 ET): 4.3 / 5 across 3,986 reviews. Google: TBD — verify before publish.
Alloy combines a solid review band with clear public language around FDA-approved estradiol and progesterone pathways and cash-pay pricing transparency. It trails Winona on menopause-specialty review volume and Ivim on review mass and dual-scope fit. Confirm current formulary and pricing directly.
How #4#10 use the same lens
- Midi (#4): specialty and insurance-first clarity with 4.0 / 1,661 Trustpilot reviews.
- Sesame (#5): 4.6 / 4,473 review signal, but a marketplace rather than a menopause medical home.
- Wisp (#6): large 4.1 / 11,506 company-wide review base with narrower sexual-health scope.
- Evernow and Gennev (#7–#8): relevant specialty scope despite thin samples.
- MyMenopauseRx and Stella (#9–#10): menopause relevance with thin samples.
Affiliations and reader checklist
Menopause Brief is an independent educational publisher. We may have a financial affiliation with some entities featured. Rank positions are determined by the published methodology; affiliation status does not substitute for Trustpilot or Google evidence.
- Open the methodology before trusting a numeral.
- Prefer dated review signals over vague “highly rated” language.
- Separate membership from medication, and FDA-approved from compounded.
- Talk with a licensed clinician about whether any pathway is appropriate.
Limitations
This deep dive summarizes methodology application as of September 23, 2026 (ET). It is not medical advice, a clinical comparative-effectiveness study, or an endorsement seal. Prices, state lists, review profiles, and offerings change. Compounded medications are not FDA-approved.
Medical disclaimer
Medical disclaimer: Content is for education only and is not medical advice, diagnosis, or treatment. We are not a medical provider, pharmacy, or telehealth clinic. Consult a licensed clinician.